8fbd035081bd09934004bfc61d79c31c5d5d9ee4

Tagged: future events

Qrons Announces Launch of its New Website in Furtherance of its Neuronal and Infectious Disease Treatments Development, Including Sepsis

NEW YORK, NY / ACCESSWIRE / August 23, 2023 / Qrons Inc. (OTCQB:QRON) an innovative biotechnology company dedicated to developing products treatments and technologies to combat neuronal and infectious diseases with a focus on antibiotic resistant bacteria, announced today the launch of its updated website at www.qrons.com. This update will provide investors and the public an overview of the company’s strides in dealing with infectious disease and sepsis with a focus on antibiotic resistant bacteria, which is becoming the most prominent and rapidly growing worldwide cause of illness and death. This is in addition to the Company’s combatting traumatic brain injuries and other neuronal diseases.

Antimicrobial resistance is an urgent global public health threat, killing at least 1.27 million people worldwide and associated with nearly 5 million deaths in 2019, according to a report released in The Lancet. In the U.S., more than 2.8 million antimicrobial-resistant infections occur each year.

Sepsis is a life-threatening medical emergency associated with a high rate of patient deaths in intensive care units. The CDC reports that each year in the U.S. more than 1.7 million people develop sepsis, and at least 350,000 adults who develop sepsis die during their hospitalization or are discharged to hospice. 1 in 3 people who die in a hospital had sepsis during that hospitalization. The US healthcare system spends about $38 billion annually on Sepsis, with costs rising approximately 8% a year.

Jonah Meer, CEO said, “The new website along with additional investor relation packages developed will allow the public to understand the special role Qrons plays in developing products treatments and technologies to tackle global health needs unaddressed by most companies. We feel we play a unique role in biotechnology innovation. We welcome investor and community engagement and feedback to assist us in our goal of commercialization.”

Read the rest